Product Description
HIB210 is an anti-C5aR1 antibody with the potential to be a best-in-class therapy for complement-mediated diseases including ANCA Associated Vasculitis (AAV), Hidradenitis Suppurativa, C3 Glomerulonephropathy and Lupus Nephritis. When compared to existing agents, it has shown greater activity against neutrophils, a cell type key to driving several IMDs. (Sourced from: https://hibio.com/science#pipeline)
Mechanisms of Action: C5 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HI-Bio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Vasculitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HIB-210-101 | P1 |
Completed |
Vasculitis |
2024-06-10 |
69% |
2024-07-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/22/2024 |
News Article |
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences |
|
01/04/2024 |
News Article |
HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases |
|
07/11/2023 |
News Article |
HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases |
|
11/01/2022 |
News Article |
Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing |